STOCK TITAN

ARCA biopharma, Inc. - $ABIO STOCK NEWS

Welcome to our dedicated page for ARCA biopharma news (Ticker: $ABIO), a resource for investors and traders seeking the latest updates and insights on ARCA biopharma stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ARCA biopharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ARCA biopharma's position in the market.

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.56%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.75%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.69%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.31%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.35%
Tags
clinical trial covid-19
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.91%
Tags
none
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.23%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.38%
Tags
ARCA biopharma, Inc.

Nasdaq:ABIO

ABIO Rankings

ABIO Stock Data

48.31M
6.74M
1.29%
71.8%
1.35%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
WESTMINSTER

About ABIO

arca was founded on the belief that a precision medicine approach to drug development, tailoring medical treatment to the individual genetic characteristics of patients, can enable more effective therapies, improve patient outcomes and reduce healthcare costs. arca’s lead development program is intended to be a direct implementation of those ideas. gencaro™ (bucindolol hydrochloride) is being developed as a potential treatment for atrial fibrillation (af). arca has identified genetic variations in cardiac receptors that we believe may predict individual patient response to gencaro™, giving gencaro™ the potential to be the first genetically-targeted prevention treatment for af.